Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00630 ...
Drug Name Alendronic acid
Molecular Weight 249.096
Molecular Formula C4H13NO7P2
CAS Number 66376-36-1
SMILES NCCCC(O)(P(O)(O)=O)P(O)(O)=O
External Links
DRUGBANK DB00630
T3DB T3D2666
PubChem Compound 2088
PDR 2567
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Melting Point 235.0 ℃ 235 ℃ https://www.tcichemicals.com/eshop/en/us/commodity/A2120/
pKa 2.72 - 2.72 - MERCK INDEX (1996)

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 0.64 % 0.64 % PO, oral;  Female, women; DRUGBANK
Bioavailability 0.59 % 0.59 % PO, oral; Male, men; DRUGBANK
Bioavailability 0.38 % 0.384 % PO, oral;  Female, women; food; food ↓ ; DRUGBANK
Bioavailability 0.35 % 0.354 % PO, oral; Male, men; food; food ↓ ; DRUGBANK
Bioavailability 0.70 % <0.7 % intravenous injection, IV; postmenopausal women; food ↓ ; The Pharmacological Basis of Therapeutics
C Max 275.0 ng/ml ~275 ng/ml postmenopausal women; The Pharmacological Basis of Therapeutics
C Max 6.7 ng/ml <5-8.4 ng/ml PO, oral; postmenopausal women; The Pharmacological Basis of Therapeutics
T Max 2.0 h 2.0 h postmenopausal women; The Pharmacological Basis of Therapeutics
Clearance 4.3 L/h 71.0 ml/min DRUGBANK
Clearance 0.0666 L/h/kg 1.11(1.00-1.22) ml/min/kg RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Volume of Distribution 28.0 L 28.0 L DRUGBANK
Volume of Distribution 0.44 L/kg 0.44(0.34-0.55) L/kg The Pharmacological Basis of Therapeutics
Half-life 86400.0 h >10 year terminal half-life; DRUGBANK
Half-life 1.0 h ~1.0 h normal,healthy; postmenopausal women; The Pharmacological Basis of Therapeutics
Half-life 102816.0 h ~11.9 year The Pharmacological Basis of Therapeutics
Eliminate Route 50.0 % 50 % Urinary excretion; DRUGBANK
Eliminate Route 44.9 % 44.9±9.3 % Urinary excretion; postmenopausal women; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 78.0 % 78 % DRUGBANK
Protein Binding 78.0 % 78 % postmenopausal women; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 10.0 mg/day 10 mg/day PO, oral Binosto alendronate sodium PDR
Max dose for adults 10.0 mg/day 70 mg/week PO, oral Binosto alendronate sodium PDR
Max dose for adults 40.0 mg/day 40 mg/day PO, oral Binosto alendronate sodium PDR
Max dose for geriatric 10.0 mg/day 10 mg/day PO, oral Binosto alendronate sodium PDR
Max dose for geriatric 10.0 mg/day 70 mg/week PO, oral Binosto alendronate sodium PDR
Max dose for geriatric 40.0 mg/day 40 mg/day PO, oral Binosto alendronate sodium PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1